A standardized protocol for modified platelet-rich plasma collection for the treatment of interstitial cystitis/bladder pain syndrome

Background: Interstitial cystitis/bladder pain syndrome (IC/BPS) is a chronic and diagnostically challenging condition with limited treatment options and poor prognosis. Platelet-rich plasma (PRP) is a potential treatment for IC/BPS. Nonetheless, conventional preparation methods are inefficient, necessitating an improved approach. Objective: To design an effective and safe protocol for collecting PRP for intravesical injections for the treatment of IC/BPS. Methods: We evaluated the feasibility of the PRP collection protocol from 17 patients. After venipuncture, blood was processed using a blood cell separator containing saline and anticoagulant. One milliliter of PRP was retained for platelet concentration analysis. Each patient received six PRP injections, and their clinical data were taken before and after the procedure to assess efficacy. Results: The mean platelet enrichment coefficient was 5.11 ± 1.27, the mean flow rate was 33.19 ± 6.77 mL/min, the mean collection volume was 125.13 ± 17.49 mL, and the mean collection time was 73.69 ± 10.17 min. Eleven patients required deep venous catheterization because superficial venipuncture failed. No adverse reactions were observed during collection, and all other blood components were retained. Three patients completed six injections, four received five injections, three received four injections, one received three injections, two received two injections, and four received one injection. After treatment, 12 of 17 patients showed symptom improvement on the Global Response Assessment scale (≥5), and all demonstrated statistically significant improvements in terms of O’Leary-Sant and Visual Analog Scale scores against baseline. One patient, however, developed gross hematuria after the fourth injection. Conclusions: The proposed PRP collection protocol is relatively safe and effective. Preliminary data suggest that intravesical PRP injection is a promising treatment for IC/BPS.
- Lee YK, Jiang YH, Jhang JF, Ho HC, Kuo HC. Changes in the ultrastructure of the bladder urothelium in patients with interstitial cystitis after intravesical injections of platelet-rich plasma. Biomedicines. 2022;10(5):1182. doi: 10.3390/biomedicines10051182
- Fang J, Wang X, Jiang W, et al. Platelet-rich plasma therapy in the treatment of diseases associated with orthopedic injuries. Tissue Eng Part B Rev. 2020;26(6):571-585. doi: 10.1089/ten.TEB.2019.0292
- Kuffler DP. Platelet-rich plasma and the elimination of neuropathic pain. Mol Neurobiol. 2013;28(2):315-332. doi: 10.1007/s12035-013-8494-7
- Jhang JF, Wu SY, Lin TY, Kuo HC. Repeated intravesical injections of platelet‐rich plasma are effective in the treatment of interstitial cystitis: A case control pilot study. Low Urin Tract Symptoms. 2018;11(2):O42-O47. doi: 10.1111/luts.12212
- Jhang JF, Ho HC, Hsu YH, Jiang YH, Kuo HC. Bladder ultrastructure and urinary cytokine abnormality in patients with recurrent urinary tract infection and the changes after intravesical platelet-rich plasma injections. Biomedicines. 2022;10(2):245. doi: 10.3390/biomedicines10020245
- Jhang JF, Lin TY, Kuo HC. Intravesical injections of platelet-rich plasma is effective and safe in treatment of interstitial cystitis refractory to conventional treatment-A prospective clinical trial. Neurourol Urodyn. 2019;38(2):703-709. doi: 10.1002/nau.23898
- Jiang YH, Kuo YC, Jhang JF, et al. Repeated intravesical injections of platelet-rich plasma improve symptoms and alter urinary functional proteins in patients with refractory interstitial cystitis. Sci Rep. 2020;10(1):15218. doi: 10.1038/s41598-020-72292-0
- Shan G, Shi L, Li Y, Liu G, Gong J. Expert forum and consensus autologous platelet-rich plasma preparation technology. Chin Blood Transfus J. 2021;7(34):677-683. doi: 10.13303/j.cjbt.issn.1004-549x.2021.07.001
- Martínez-Martínez A, Ruiz-Santiago F, García-Espinosa J. Platelet-rich plasma: Myth or reality-Radiología (Engl Ed). 2018;60(6):465-475. doi: 10.1016/j.rx.2018.08.006
- Hegde V, Setia R, Soni S, et al. Prophylactic low dose continuous calcium infusion during peripheral blood stem cell (PBSC) collections to reduce citrate related toxicity. Transfus Apher Sci. 2016;54(3):373-376. doi: 10.1016/j.transci.2015.11.015
- Everts P, Onishi K, Jayaram P, Lana JF, Mautner K. Platelet-rich plasma: New performance understandings and therapeutic considerations in 2020. Int J Mol Sci. 2020;21(20):7794. doi: 10.3390/ijms21207794
- Andia I, Abate M. Platelet-rich plasma: Underlying biology and clinical correlates. Regen Med. 2013;8(5):645-658. doi: 10.2217/rme.13.59
- Ahmed M, Reffat SA, Hassan A, Eskander F. Platelet-rich plasma for the treatment of clean diabetic foot ulcers. Ann Vasc Surg. 2017;38:206-211. doi: 10.1016/j.avsg.2016.04.023
- Yu WR, Jhang JF, Jiang YH, Kuo HC. The pathomechanism and current treatments for chronic interstitial cystitis and bladder pain syndrome. Biomedicines. 2024;12(9):2051. doi: 10.3390/biomedicines12092051
- Zhang Y, Liu G, Xu Y, Shan G. Application of component separator NGLXCF-3000-N13D in the preparation of platelet rich plasma. Mil Med J S Chin. 2020;34(10):755-757. doi: 10.13730/j.issn.1009-2595.2020.10.018
- Arora G, Arora S. Platelet‐rich plasma-where do we stand today? A critical narrative review and analysis. Dermatol Ther. 2021;34(1):e14343. doi: 10.1111/dth.14343
- Wu PI, Diaz R, Borg-Stein J. Platelet-rich plasma. Phys Med Rehabil Clin N Am. 2016;27(4):825-853. doi: 10.1016/j.pmr.2016.06.002
- Ojea-Pérez AM, Acebes-Huerta A, Arias-Fernández T, Gutiérrez L, Muñoz-Turrillas MC. Implementation of a closed platelet-rich plasma preparation method using the local blood bank infrastructure at the principality of Asturias (Spain): Back to basic methodology and a demographics perspective after 1 year. Transfus Apher Sci. 2019;58(5):701-704. doi: 10.1016/j.transci.2019.08.016
- Kuffler DP. Variables affecting the potential efficacy of PRP in providing chronic pain relief. J Pain Res. 2019;12:109-116. doi: 10.2147/JPR.S190065
- Date AA, Kates M, Yoshida T, et al. Preclinical evaluation of a hypotonic docetaxel nanosuspension formulation for intravesical treatment of non-muscle-invasive bladder cancer. Drug Deliv Transl Res. 2021;11(5):2085-2095. doi: 10.1007/s13346-020-00870-w
- Rajaganapathy BR, Chancellor MB, Nirmal J, Dang L, Tyagi P. Bladder uptake of liposomes after intravesical administration occurs by endocytosis. PLoS One. 2015;10(3):e0122766. doi: 10.1371/journal.pone.0122766
- Philip J, Sarkar RS, Pathak A. Adverse events associated with apheresis procedures: Incidence and relative frequency. Asian J Transfus Sci. 2013;7(1):37-41. doi: 10.4103/0973-6247.106730
- He M, Chen T, Lv Y, et al. The role of allogeneic platelet-rich plasma in patients with diabetic foot ulcer: Current perspectives and future challenges. Front Bioeng Biotechnol. 2022;10:993436. doi: 10.3389/fbioe.2022.993436